Please ensure Javascript is enabled for purposes of website accessibility

Michael Kors Jumps, but J.C. Penney Falters Again

By Jeremy Bowman – Feb 4, 2014 at 10:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Earnings season moved on as Michael Kors scored a big win, but J.C. Penney continued to struggle.

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Following Monday's collapse, stocks rebounded today as the market's focus returned to earnings season after fears about a sharp drop in new orders sparked a sell-off yesterday. Today, the Dow Jones Industrial Average (^DJI 0.45%) finished 72 points, or 0.5% higher, as drugmakers Merck and Pfizer (PFE 0.74%) led the way, each gaining 2.8%, after Pfizer got an upgrade from Jeffries. The research firm said the company's reorganization and promising cancer treatment should help drive long-term growth. Like many drugmakers, Pfizer has struggled with the so-called "patent cliff" as a number of its blockbuster drugs, including Lipitor, have recently lost their patent. The main focus of the company's restructuring is to divide operations into groups, with one focusing on newer drugs and the other examining products approaching the cliff.

Elsewhere, Michael Kors (CPRI -0.24%) finishing up 11% after the fashion label once again delivered blowout quarter, and coming against an otherwise dismal holiday season, the performance looked especially impressive. Kors delivered earnings of $1.11 per share, well ahead of the analyst mark at $0.86, while sales shot up 59% on a whopping 28% same-store sales growth. The comparable sales figure shows that growth came both organically and through as the clothing-maker appears to be firing on cylinders. Shares are up over 60% over the past year, but based on today's report they have a lot more room to run.

J.C. Penney (JCPN.Q) wasn't faring as well, falling 11% after releasing comparable sales numbers for its fourth quarter. The struggling retailers said same-store sales grew 2%, but that seemed to disappoint the market, which was hoping for a better performance as Penney desperately needs to mend its bottom line. Analysts had estimated growth in the category at 4.2%. Also disconcerting to investors was Penney's lack of information on gross margin, indicating that those increased sales may have come from steep discounting, meaning its net loss may have actually gotten worse in the quarter.

Jeremy Bowman has no position in any stocks mentioned. The Motley Fool recommends Michael Kors Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$34,347.03 (0.45%) $152.97
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Capri Holdings Stock Quote
Capri Holdings
CPRI
$53.30 (-0.24%) $0.13
J.C. Penney Stock Quote
J.C. Penney
JCPN.Q

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.